Cargando…
Relapsing/refractory HL after autotransplantation: which treatment?
For advanced-stage Hodgkin lymphoma (HL), front-line chemotherapy, alone or in combination with radiotherapy, leads to 5-year progression-free survival (PFS) rates and freedom-from-treatment failure (FFTF) rates of 70-85%, regardless of the chemotherapy regimen applied. Patients with HL experiencing...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944654/ https://www.ncbi.nlm.nih.gov/pubmed/32525132 http://dx.doi.org/10.23750/abm.v91iS-5.9912 |
_version_ | 1783662714637254656 |
---|---|
author | Di Renzo, Nicola Gaudio, Francesco Carlo Stella, Carmelo Oppi, Sara Pelosini, Matteo Sorasio, Roberto Stelitano, Caterina Rigacci, Luigi |
author_facet | Di Renzo, Nicola Gaudio, Francesco Carlo Stella, Carmelo Oppi, Sara Pelosini, Matteo Sorasio, Roberto Stelitano, Caterina Rigacci, Luigi |
author_sort | Di Renzo, Nicola |
collection | PubMed |
description | For advanced-stage Hodgkin lymphoma (HL), front-line chemotherapy, alone or in combination with radiotherapy, leads to 5-year progression-free survival (PFS) rates and freedom-from-treatment failure (FFTF) rates of 70-85%, regardless of the chemotherapy regimen applied. Patients with HL experiencing disease progression during or within 3 months of front-line therapy (primary refractory) and patients whose disease relapses after a complete response have a second chance of treatment. The standard of care for relapsed or refractory HL is second-line chemotherapy followed by autologous stem cell transplantation (ASCT), which can induce long-term remission in approximately 40-50% of patients. However, HL recurrence occurs in about 50% of patients after ASCT, usually within the first year, and represents a significant therapeutic challenge. Allogeneic transplantation from HLA-matched donors represents the standard of care for patients with HL relapsing after- or refractory to ASCT. |
format | Online Article Text |
id | pubmed-7944654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Mattioli 1885 |
record_format | MEDLINE/PubMed |
spelling | pubmed-79446542021-03-10 Relapsing/refractory HL after autotransplantation: which treatment? Di Renzo, Nicola Gaudio, Francesco Carlo Stella, Carmelo Oppi, Sara Pelosini, Matteo Sorasio, Roberto Stelitano, Caterina Rigacci, Luigi Acta Biomed How I Treat For advanced-stage Hodgkin lymphoma (HL), front-line chemotherapy, alone or in combination with radiotherapy, leads to 5-year progression-free survival (PFS) rates and freedom-from-treatment failure (FFTF) rates of 70-85%, regardless of the chemotherapy regimen applied. Patients with HL experiencing disease progression during or within 3 months of front-line therapy (primary refractory) and patients whose disease relapses after a complete response have a second chance of treatment. The standard of care for relapsed or refractory HL is second-line chemotherapy followed by autologous stem cell transplantation (ASCT), which can induce long-term remission in approximately 40-50% of patients. However, HL recurrence occurs in about 50% of patients after ASCT, usually within the first year, and represents a significant therapeutic challenge. Allogeneic transplantation from HLA-matched donors represents the standard of care for patients with HL relapsing after- or refractory to ASCT. Mattioli 1885 2020 2020-05-25 /pmc/articles/PMC7944654/ /pubmed/32525132 http://dx.doi.org/10.23750/abm.v91iS-5.9912 Text en Copyright: © 2020 ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution 4.0 International License |
spellingShingle | How I Treat Di Renzo, Nicola Gaudio, Francesco Carlo Stella, Carmelo Oppi, Sara Pelosini, Matteo Sorasio, Roberto Stelitano, Caterina Rigacci, Luigi Relapsing/refractory HL after autotransplantation: which treatment? |
title | Relapsing/refractory HL after autotransplantation: which treatment? |
title_full | Relapsing/refractory HL after autotransplantation: which treatment? |
title_fullStr | Relapsing/refractory HL after autotransplantation: which treatment? |
title_full_unstemmed | Relapsing/refractory HL after autotransplantation: which treatment? |
title_short | Relapsing/refractory HL after autotransplantation: which treatment? |
title_sort | relapsing/refractory hl after autotransplantation: which treatment? |
topic | How I Treat |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944654/ https://www.ncbi.nlm.nih.gov/pubmed/32525132 http://dx.doi.org/10.23750/abm.v91iS-5.9912 |
work_keys_str_mv | AT direnzonicola relapsingrefractoryhlafterautotransplantationwhichtreatment AT gaudiofrancesco relapsingrefractoryhlafterautotransplantationwhichtreatment AT carlostellacarmelo relapsingrefractoryhlafterautotransplantationwhichtreatment AT oppisara relapsingrefractoryhlafterautotransplantationwhichtreatment AT pelosinimatteo relapsingrefractoryhlafterautotransplantationwhichtreatment AT sorasioroberto relapsingrefractoryhlafterautotransplantationwhichtreatment AT stelitanocaterina relapsingrefractoryhlafterautotransplantationwhichtreatment AT rigacciluigi relapsingrefractoryhlafterautotransplantationwhichtreatment |